Effect of lactuside B on the expression of CHOP mRNA in rats' cerebral cortex and hippocampus after cerebral ischemia-reperfusion injury / 中国药学杂志

ABSTRACT

OBJECTIVE: To investigate the effect of lactuside B on CHOP mRNA expression in rat's cerebral cortex and hippocampus after cerebral ischemia injury. METHODS: Male SD rats of 280-320 g were randomly given brain ischemia-reperfusion treatment for 24 and 72 h respectively and then divided into sham operation group, model group, positive control group, and lactuside B 12.5 mg · kg-1 group, 25 mg · kg-1 group and 50 mg · kg-1 group. There were a total of 12 groups with 4 rats in each group. The cerebral ischemia-reperfusion model was established by cerebral artery occlusion for 2 h. The animals with neurological missing symptom scores of 1-3 were selected for the experiment. All the animals were intraperitoneally injected corresponding experimental drugs after reperfusion for 24 and 72 h and then sacrificed. RT-PCR was used to detected the expression of CHOP mRNA in the cerebral and hippocampus at different time. RESULTS: After cerebral ischemia-reperfusion injury for 24 and 72 h, the neurological deficits scores of the model group animals were significantly higher compared with the sham group (P < 0.01); the neurological deficit scores of the animals were decreased for positive control group and all lactuside B groups compared with model group (P < 0.01). All of the three dosage(12.5, 25 and 50 mg · kg-1) of lactuside B could reduce CHOP mRNA expression in cerebral cortex and hippocampus compared with the model group (P < 0.05, P < 0.01), and the majority of lactuside B groups were superior to the positive control drug nimodip-ine(P < 0.01). There was a good dose-effect relationship for lactuside B in general, but only the middle dose group showed good time-effect relationship. CONCLUSION: The results suggest that the anti-cerebral ischemia effect of lactuside B may be related with the down-regulation of CHOP mRNA expression in cortex and hippocampus. Lactuside B is worthy of development. Copyright 2013 by the Chinese Pharmaceutical Association.